search
Back to results

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

Primary Purpose

Type 1 Diabetes, De Novo Lipogenesis

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Oral Glucose Tolerance Test
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Type 1 Diabetes

Eligibility Criteria

13 Years - 22 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • HbA1c >8.5% for the group with poorly controlled diabetes
  • HbA1c <7.5% for the well-controlled patients
  • T1D for at least 12 months (T1D groups only)
  • Negative pregnancy test (all groups)

Exclusion Criteria:

  • Baseline creatinine >1
  • Being on medications affecting glucose concentrations other than insulin
  • Positive pregnancy test
  • Endocrinopathies

Sites / Locations

  • Yale University School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Poorly-controlled T1D

Controlled T1D

Lean controls

Arm Description

Patients in this group will have poorly-controlled T1D (HbA1c >8.5%).

Patients in this group will have T1D and achieve targeted glycemic control (HbA1c <7.5%).

Patients in this group will not have T1D.

Outcomes

Primary Outcome Measures

Fractional hepatic DNL
% Fractional hepatic DNL

Secondary Outcome Measures

Full Information

First Posted
September 17, 2019
Last Updated
February 8, 2023
Sponsor
Yale University
Collaborators
Juvenile Diabetes Research Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT04101045
Brief Title
Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes
Official Title
Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Terminated
Why Stopped
During the pandemic the funding agency stopped funding studies.
Study Start Date
November 21, 2019 (Actual)
Primary Completion Date
March 30, 2022 (Actual)
Study Completion Date
March 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
Juvenile Diabetes Research Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to quantitate hepatic de novo lipogenesis (DNL) in youth with poorly-controlled type 1 diabetes (T1D) (HbA1c >8.5%), youth with T1D who achieve targeted glycemic control (HbA1c <7.5%) and lean controls. Hypothesis: Youth with poor glycemic control experience higher fractional hepatic DNL during the fasting and the postprandial states than youth who achieve targeted glycemic control and lean controls.
Detailed Description
What is not known, is whether hepatic de novo lipogenesis (DNL) contributes to dyslipidemia in this in patients with type 1 diabetes (T1D). The aim of the study is to test the hypothesis that an enhanced rate of DNL largely contributes to dyslipidemia occurring in youth with poorly-controlled T1D. According to this hypothesis, youth with poorly-regulated T1D experience a state of persistent insulin independent, highly variable fluctuations of glucose, and other sugars, through the glycolytic pathway that result in an enhancement of hepatic DNL and an increased production of triglycerides (TG). Newly-formed TG are packaged into large-VLDL that are secreted into the circulation contributing to an increase in plasma TG. When the TG concentration in the hepatocytes exceeds the ability of the liver to secrete TG, the latter start accumulating leading to hepatic steatosis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes, De Novo Lipogenesis

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Poorly-controlled T1D
Arm Type
Active Comparator
Arm Description
Patients in this group will have poorly-controlled T1D (HbA1c >8.5%).
Arm Title
Controlled T1D
Arm Type
Active Comparator
Arm Description
Patients in this group will have T1D and achieve targeted glycemic control (HbA1c <7.5%).
Arm Title
Lean controls
Arm Type
Active Comparator
Arm Description
Patients in this group will not have T1D.
Intervention Type
Diagnostic Test
Intervention Name(s)
Oral Glucose Tolerance Test
Intervention Description
Each participant consumes a dinner scaled to his/her energy needs which is prepared by the metabolic kitchen. Dinner will be provided beforehand if patient does this portion at home. The participant consumes the first of three doses of D2O. Two additional doses of D20 are given at on day 1 and on day 2. The total D2O given (3 ml per kg of body water) is designed to raise body deuterium levels to 0.3% and is administered as described above to maintain steady state until the end of the study. At the HRU, an IV catheter will be inserted in order to collect blood to assess DNL. Blood draws begin during the fasting state to assess basal rates of DNL and then for six hours after the consumption of a glucose/fructose beverage (75g glucose and 25g fructose ) to assess postprandial rates of DNL. Blood draws will be taken 15 minutes before ingestion of the sugar beverage, then for every half hour for 6 hours.
Primary Outcome Measure Information:
Title
Fractional hepatic DNL
Description
% Fractional hepatic DNL
Time Frame
Baseline to Six hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: HbA1c >8.5% for the group with poorly controlled diabetes HbA1c <7.5% for the well-controlled patients T1D for at least 12 months (T1D groups only) Negative pregnancy test (all groups) Exclusion Criteria: Baseline creatinine >1 Being on medications affecting glucose concentrations other than insulin Positive pregnancy test Endocrinopathies
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicola Santoro, MD, PhD
Organizational Affiliation
Assistant Professor of Pediatrics (Endocrinology)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale University School of Medicine
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32561908
Citation
Monga Kravetz A, Testerman T, Galuppo B, Graf J, Pierpont B, Siebel S, Feinn R, Santoro N. Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth. J Clin Endocrinol Metab. 2020 Oct 1;105(10):e3575-85. doi: 10.1210/clinem/dgaa382.
Results Reference
derived

Learn more about this trial

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

We'll reach out to this number within 24 hrs